SEC Form 4 · accession 0001104659-26-090344
iBio, Inc. · IBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Molly Carr
Officer — Chief Medical Officer
Period of report
Jul 31, 2026
Accepted (ET)
Aug 4, 2026 · 4:01 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001420720
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $1.40 | Jul 31, 2026 | A | 430,000 | A | Jul 31, 2027 | Jul 30, 2036 | Common Stock | 430,000 | 430,000 | D |
Explanation of responses
- F1Stock option granted as an inducement award to the Reporting Person that was granted outside of the iBio, Inc. 2023 Omnibus Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4) on July 31, 2026 (the "Grant Date").
- F2Vesting 25% on the one-year anniversary of the Grant Date, with an additional 6.25% vesting every three months thereafter, provided the Reporting Person remains employed by iBio, Inc. through each applicable vesting date.